127 results about "Cytokeratin" patented technology

Provided are methods for the rapid detection of ovarian cancer. The methods employ a multiplex immunoassay to detect levels of two or more of the markers EGF, G-CSF, IL-6, IL-8, CA-125, VEGF, MCP-1, anti-IL6, anti-IL8, anti CA-125, anti-c-myc, anti-p53, anti-CEA, anti-CA 15-3, anti-MUC-1, anti-survivin, anti-bHCG, anti-osteopontin, anti-PDGF, anti-Her2 / neu, anti-Akt1, anti-cytokeratin 19, cytokeratin 19, EGFR, CEA, kallikrein-8, M-CSF, FasL, ErbB2 and Her2 / neu in a sample of the patient's blood, where the presence of abnormal levels of two or more of the markers indicates the presence of ovarian cancer in the patient. An array also is provided to quantitate levels of these markers in a patient's blood. Also provided is a method of predicting onset of clinical ovarian cancer comprising determining the change in concentration over time of two or more of anti-Her2 / neu, anti-MUC-1, anti-c-myc, anti-p53, anti-CA-125, anti-CEA, anti-CA 72-4, anti-PDGFRα, IFNγ, IL-6, IL-10, TNFα, MIP-1α, MIP-1β, EGFR and Her2 / neu in a patient's blood.

A population of embryonic epithelial cells produced in vitro from embryonic stem cells. In one embodiment, at least 45% of the cells express cytokeratin, for example, cytokeratin-7.

The invention provides a reagent for diagnosing cervical cancer, which can not only detect the presence or absence of cervical cancer but can also distinguish squamous cell carcinoma and adenocarcinoma from each other, a method for screening cervical cancer by using the reagent, particularly a screening method capable high speed processing by utilizing flow cytometry. The reagent comprises a first labeled antibody reacting with gland cells, a second labeled antibody reacting with adenocarcinoma cells and a third labeled antibody reacting with atypical cervical squamous cells, the antibodies being labeled with mutually distinguishable labels respectively. Preferably, at least one selected from the group consisting of MUC1 antibody, cytokeratin 7 antibody, and cytokeratin 18 antibody is used as the first labeled antibody, at least one selected from the group consisting of cytokeratin 8 antibody and HIK1083 antibody is used as the second labeled antibody, and at least one member selected from the group consisting of NMP179 antibody, p16INK4A antibody, Ki-67 antibody, p53 antibody, p21 antibody, EMA antibody, CEA antibody and MIB-1 antibody is used as the third labeled antibody.

Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.

The invention relates to the medical field of immunoassay, more specially, the invention provides a cytokeratin 19 fragment chemiluminescent immunoassay detection kit and a preparation method thereof. The kit of the invention comprises 1) cytokeratin 19 fragment CYFRA21-1 calibrators, 2) solid-phase vectors which are coated by cytokeratin 19 fragment CYFRA21-1 monoclonal antibodies, 3) cytokeratin 19 fragment CYFRA21-1 monoclonal antibodies which are marked by enzyme and 4) chemiluminescent substrates which are acted by the enzyme. Further, the preparation method of the kit according to the invention comprises the following steps: 1) preparing the cytokeratin 19 fragment CYFRA21-1 calibrators, 2) coating the solid-phase vectors with the cytokeratin 19 fragment CYFRA21-1 monoclonal antibodies, 3) marking the cytokeratin 19 fragment CYFRA21-1 monoclonal antibodies with the enzyme, 4) packaging the calibrators, the enzyme markers and the chemiluminescent substrates and 5) assembling finished products. The kit of the invention has the advantages of convenience, rapidness, sensitivity, stability and the like.

The invention provides a variety of reagents for use in the diagnosis and management of cancer, particularly breast cancer. cDNA microarray technology was used to identify genes whose expression profile across a large group of tumor samples correlates with that of cytokeratin 5 and cytokeratin 17, markers for basal cells of the normal mammary lactation gland. The invention demonstrates that tumors that express cytokeratin 5 / 6 and / or 17 have a poor prognosis relative to tumors overall. The invention provides basal marker genes and their expression products and uses of these genes for diagnosis of cancer and for identification of therapies for cancer. In particular, the invention provides basal marker genes including cadherin3, matrix metalloproteinase 14, and cadherin EGF LAG seven-pass G-type receptor 2. The invention provides antibodies to the polypeptides expressed by these genes and methods of use thereof.

The invention belongs to the technical field of biology and relates to a protein chip reagent kit and a method for comprehensively detecting a lung cancer marker. The protein chip reagent kit for comprehensively detecting the lung cancer marker comprises: (1) a chip (1) and (2) a reaction agent and a detection agent, wherein a plurality of specific antibodies are simultaneously fixed on the chip, can generate antibody-antigen reaction with the lung cancer marker and are fixed on a bottom film of the chip to form a plurality of independent recognition sites; and the reaction agent and the detection agent are used for detecting whether a matter capable of generating antibody-antigen reaction with the specific antibodies exists in a sample to be detected or not through a TRFIA (Time Resolved Fluorescence Immunoassay) method. The reagent kit and the method have the beneficial effects that the six indexes of NSE (Neuron Specific Enolase), SCC (Squamous Cell Carcinoma), CEA (Carcino Embryonie Antigen), CA (Carbonic Anhydrase) 19-9, CYFR (Cytokeratin Fragment) A21-1 and pro-GRP (Glass Reinforced Plastic) can be simultaneously detected, the detection accuracy is improved, the repetitive experimental steps are reduced, and the time and the cost are saved.

Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.

The invention relates to a quantum dot fluorescent probe and application thereof. The invention is characterized in that the quantum dot fluorescent probe utilizes a difunctional cross-linking agent long-chain succinimidyl-4-[N-maieimidomethyl]cyclohexane-1-carboxy-[6-amidocaproate] (SMCC) to undergo a cross-linking reaction with an amino group on the surface of an amino quantum dot; a maleimide group is produced on the surface of the quantum dot; a to-be-labeled antibody is reduced by a reducing agent dithiothreitol (DTT) so as to reduce a disulfide bond into a mercapto group; and the mercapto group and the maleimide group form a covalent bond so as to realize labeling of the quantum dot with the antibody. The quantum dot fluorescent probe is applied to (1) detection of one protein oncofetal antigen or (2) detection of a plurality of protein CEA, euron-specific enolase (NSA) and a cytokerain fragment 19CYFRA21-1, wherein the detection limit of detection (1) is 38 pg / ml, and the detection limit of detection (2) is 0.9 ng / ml.

The invention provides a method for determining the histotype of a non-small cell lung cancer tumor which comprises: (a) determining the levels of expression of each of thyroid transcription factor-1, cytokeratin-5, cytokeratin-13 and epidermal growth factor receptor in a sample from the non-small cell lung cancer tumor; (b) calculating a score based on the levels of expression determined in step (a); and (c) comparing the score obtained in step (b) with a predetermined reference score associated with histotypes of non-small cell lung cancer; wherein the tumor is determined to be an adenocarcinoma if the score obtained in (b) is greater than the predetermined reference score and wherein the tumor is determined to be a squamous cell carcinoma if the score obtained in (b) is less than the predetermined reference score.

A method of detecting liver damage in a subject comprises measuring the level of caspase-3 generated cytokeratin-18 fragments in the bodily sample. The level of measuring the level of caspase-3 generated cytokeratin-18 fragments is then correlated with liver disease progression.

The invention provides a method for evaluating postoperative recurrence risk of hepatocellular carcinoma patients prepared to be treated by radical operation of hepatocellular carcinoma on the basis of combined detection of cytokeratin 19 (CK19) and Glypican-3 (GPC3), tumor cells differentiation status and number of tumors as the indexes. According to the method, patients can be reasonably screened before operation so as to reduce metastasis and recurrence after radical operation of tumor. In addition, metastasis and recurrence risks after radical operation of hepatocellular carcinoma patients can be evaluated according to the method so as to further guide clinicians to carry out close monitoring and early treatment for cases with high risks of metastasis and recurrence.

The invention discloses a multiple stain reagent and a detection method for identifying a breast myoepithelial lesion. The multiple stain reagent comprises 20% of mouse anti-human CK8 / 18 immunohistochemical monoclonal antibody, 20% of ready-to-use calmodulin mouse anti-human monoclonal antibody, 20% of ready-to-use cytokeratin mouse anti-human monoclonal antibody, 20% of ready-to-use P63 protein mouse anti-human monoclonal antibody, and 20% of actin HHF-35 anti-human monoclonal antibody. When a breast myoepithelial cell is marked, the myoepithelial cell has strong specificity and sensibility, and different target antigens in the same target cell can be identified, so that a cell nucleus, a cell membrane and a cytoplasm can be stained synchronously, the reactivity and the sensibility of the myoepithelial cell are markedly improved, basic structures of a breast acinus and a catheter can be indicated more objectively, and a good assistance effect is exerted on the diagnosis of the breast lesion.

A method for the diagnosis and identification of new or residual lung cancer is disclosed which uses newly identified markers for lung cancer including syndecan 1, collagen 1 alpha 2, and two novel proteins, 7013 and 7018. The method involves identification of the lung cancer markers is blood from a patient. It is envisioned that at least one marker may be used or any mixture of the four. The method may also include the identification of cytokeratin-19.

The present invention provides a pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease (COPD) comprising cytokeratin 18 protein as an active ingredient. The present invention also provides a diagnostic composition and a diagnostic kit for diagnosing COPD comprising cytokeratin 18 protein. The present invention further provides a composition for screening a therapeutic agent for COPD, comprising one or more of cytokeratin 18 protein or autoantibodies to cytokeratin 18 obtained from patients with COPD and a method for screening a therapeutic agent for COPD using this composition. The present invention still further provides methods for diagnosing, preventing or treating COPD using cytokeratin 18 protein.

Cytokeratin (CK)+ / CD45− / DAPI+ cells in the blood of cancer patients have been considered by most as circulating tumor cells (CTCs). Different methods of isolating CTCs results in a wide range of numbers and subgroups of CTCs from same patient. As a result, the clinical significance of the number of CTCs becomes cloudy. Provided herein is methodology to categorize CTCs into morphologically distinct subpopulations, and to use one of the subpopulations in methods for predicting overall survival of a patient having cancer.

The invention discloses a kit for predicating lung cancer risk for high-risk groups among the China urban population on the basis of CT (computed tomography) images and biomarker spectrums. The kit comprises a reagent for measuring the expression quantity of serum protein spectrums of the following four biomarkers including pro-gastrin-releasing peptides, carcino-embryonic antigens, fragments of cytokeratin 19 and squamous-cell carcinoma antigens. The kit can be used for accurately predicating the lung cancer risk in combination of CT imageology parameters including nodule diameters, spicule signs and positions and other clinical indexes including age, the smoking history, the history of malignant tumor and genders.

The invention relates to a colloidal gold chromatographic test strip for cytokeratin 19 (CK19) and a preparation method thereof. The colloidal gold chromatographic test strip comprises a base plate, a sample pad, a combination pad, a nitrocellulose membrane, and a water absorbing pad. The sample pad, combination pad, nitrocellulose membrane, and water absorbing pad are sequentially pasted on one end of the base plate. The test strip is characterized in that the combination pad is made of a glass fiber membrane, a CK19 monoclone antibody-colloidal gold conjugate is painted on the glass fiber membrane; a detection T line and a quality control C line are embedded in the nitrocellulose membrane; the T line is the polyclonal antibody of CK19, and the C line is the corresponding second antibody of the CK19 monoclonal antibody. The prepared colloidal gold chromatographic test strip has the advantages of user-friendliness, fastness, high sensitivity, and good specificity, can be used during the operation, can provide guides for the post operation scheme, and has an important clinical meaning.

Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin and ABCG2 have been identified as molecular markers for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin and / or ABCG2-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.

The present invention relates to enrichment and / or identification of fetal cells of a maternal blood sample using fetal cell specific ligands and / or fetal cell specific hybridization probes wherein the ligand or probes are directed to an endothelial / mesenchymal marker, e.g. CD105, CD146 or CD141, in a first round of enrichment and the ligand or probes, in a second round of enrichment, are directed to an epithelial marker, e.g. a cytokeratin, such as CK7, CK8, CK18 or CK19. Enriched or identified fetal cells may be subjected to steps of detection or diagnosis, wherefore the present invention enables non- invasive 5 prenatal diagnostics.

The invention discloses a method for felt proofing on a wool fabric through proteinase K and belongs to the technical field of application of dyeing and finishing and processing of the wool fabric inthe wool spinning industry. The problems are solved that during common proteinase felt proofing, the damage to wool strength is large, and the function of degrading keratin in a scale layer is small.The aim of optimizing proteinase felt proofing on the wool fabric is achieved. The optimization technology comprises the steps that the pure wool fabric is pretreated through urea peroxide, CMC is closed through chitosan oligosaccharide, and then the wool fabric is treated through the proteinase K. According to the wool fabric treated through the method, the felt proofing performance is obviouslyimproved, and the damage to the fabric strength is lowered. According to the method, the proteinase K is introduced into wool felt proofing for the first time, the wool scale cytokeratin is effectively degraded through the proteinase K, the good felt proofing effect on wool is achieved, and traditional chlorination felt proofing can be replaced.

The invention discloses a model for predicating lung cancer risks for people suffering from pulmonary nodules among the China urban population on the basis of CT (computed tomography) images and biomarker spectrums. The model comprises biomarkers, enzyme-labeled antibodies of the biomarkers, a carbonate buffer solution with the pH value being 9.6, a phosphate buffer solution with a pH value being 7.4, a serum protein diluent, a stop solution, a tetramethyl benzidine substrate solution, serum of normal people and positive control serum; the biomarkers are four biomarkers including pro-gastrin-releasing peptides, carcino-embryonic antigens, fragments of cytokeratin 19 and squamous-cell carcinoma antigens and are combined with CT imageology parameters and other clinical indexes. The model can assist in screening of lung cancer.

The invention relates to a method and system for grouping liver transplantation prognostic conditions for a patient with hepatocellular carcinoma, and a kit, and provides a method of carrying out stricter liver transplantation preoperative receptor screening on a patient with hepatocellular carcinoma meeting 'Milan criteria' and a method of predicting tumor recurrence and metastasis risks in a liver transplantation postoperative patient, based on the joint detection of cytokeratin 19 (CK19) and glypican-3 (GPC3) and the patient's serum alpha-fetoprotein (AFP) concentration as a technical index. According to the method, it is possible to reduce post-transplantation tumor recurrence, and it is also possible to guide clinicians to carry out intensive monitoring or early treatment for post-liver transplantation cases with high metastasis and recurrence risks.

The present invention discloses a method and kit for screening early-stage non-small cell cancer. According to the method, early-stage non-small cell cancer is screened through combined detection of keratanase protein (YKL-40), cytokeratin 19 (CYFRA21-1) and carcinoembryonic antigen (CEA). With the method, the early-stage non-small cell cancer prediction accuracy can be improved.

The invention relates to a polymolecular marker composition used for lung cancer diagnosis. The invention discloses a group of lung cancer combined markers, including hepatocyte growth factor, C-reactive protein, prolactin, Wnt induced signal path protein 1 (WISP1), imprinting site binding factor (BORIS), CA125, cytokeratin 19 segment and carcino-embryonic antigen. In serum of lung cancer patients, the expression of these proteins is obviously higher than that of non-cancer patients. These markers are combined to be applied to clinical diagnosis, so that the accuracy of lung cancer diagnosis can be obviously improved, and early-stage patients suffering from lung cancer can be detected.

The inventors of the present invention have surprisingly discovered that EGFR expression in nonmetastatic breast cancer patients with CK-negative CTCs could induce EMT process. A simultaneous detection of both EGFR and EMT markers (VIM and Slug) in CTCs might improve prognostic or predictive information in patients with operable breast cancer.

A method for determination of CK19 mRNA is provided characterized in that a part of CK19 mRNA is amplified using a first primer hybridizing to a region located on a first exon of the CK19 gene and a second primer hybridizing to a region located on a second exon of the CK19 gene locating downstream of the first exon. The amplificate is than detected using two kinds of probes.

The invention relates to a probe and a kit for circulating tumor cell and neutrophil leucocyte identification. The probe for circulating tumor cell and neutrophil leucocyte identification contains fluorescent dye A, CD45, cytokeratin and ANCA; the cytokeratin, the CD45 and the ANCA have fluorescent dye B with different colors. The kit for circulating tumor cell and neutrophil leucocyte identification comprises a probe. The fluorescent dye A, the CD45, the cytokeratin and the ANCA dyed CTC are used, so that the circulating tumor cells and the neutrophil leucocytes can be distinguished; the number of the circulating tumor cells in the peripheral blood of the lung cancer patient can be precisely identified; the reoccurrence and metastasis possibility of the lung cancer patient can be accurately predicted.